Description

Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester is a high-purity, advanced pharmaceutical intermediate characterized by its complex, multi-functional molecular structure. This compound is critical for the synthesis of novel active pharmaceutical ingredients (APIs), particularly in therapeutic areas requiring targeted molecular scaffolds. It is primarily utilized by research institutions and pharmaceutical manufacturers engaged in the development of new chemical entities and process optimization.

Application

• Pharmaceutical Intermediate: Key building block in the research and development of new drug candidates, especially in oncology and central nervous system (CNS) therapeutic areas.
• Process Chemistry: Used in route scouting and scale-up studies for the commercial manufacturing of complex APIs.
• Medicinal Chemistry Research: Serves as a versatile scaffold for structure-activity relationship (SAR) studies and lead optimization in drug discovery programs.
• Reference Standard: Employed as an analytical standard for quality control and method validation in pharmaceutical analysis.
• Custom Synthesis: A starting material for the tailored synthesis of specialized derivatives and analogs for proprietary research.

Basic Information

Item	Details
Product Name	Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester
CAS No.	830346-49-1
Molecular Formula	C26H24BrF4N3O4
Molecular Weight	598.39 g/mol
Synonyms	tert-Butyl (R)-2-(5-bromo-3-((2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-2-phenylethylcarbamate; (R)-tert-Butyl 2-(5-bromo-3-((2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-2-phenylethylcarbamate; CAS 830346-49-1; UNII-7K3Q8WJ8QN; 1(2H)-Pyrimidineacetic acid, 5-bromo-α-[[(1,1-dimethylethoxy)carbonyl]amino]-3,6-dihydro-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-, (αR)-; tert-Butyl N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phenylethyl]carbamate
EINECS	Contact for details

Quality Control

Our Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing to ensure identity, purity, and consistency. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting key parameters such as assay, chiral purity, and impurity profiles. Our quality protocols are designed to support cGMP compliance for pharmaceutical applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (15-25°C). The product is sensitive to strong acids and organic solvents; keep away from incompatible materials. For long-term storage, consider inert atmosphere conditions to ensure stability.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.